Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 9;35(6):428-436.
doi: 10.1055/s-0042-1758048. eCollection 2022 Nov.

Medical Treatment Options for Ulcerative Colitis

Joseph Sleiman  1 , Mehak Bassi  2 , Evangelos Tsipotis  3 , Aline Charabaty  4
Affiliations
Review

Medical Treatment Options for Ulcerative Colitis

Joseph Sleiman et al. Clin Colon Rectal Surg. .

Abstract

The landscape of management of ulcerative colitis, a type of inflammatory bowel disease, continues to change with advancement in pharmaceutical options as well as clinical treatment targets. Ulcerative colitis primarily involves the superficial layers of the large bowel, and cause active inflammation that can affect the colon from the rectum to the cecum in a relapsing and a remitting course. In this review, we provide evidence-based guidance on the selection of appropriate medical therapies based on individual patient and disease characteristics, with a focus on biologics and small molecules. We also review the role of surgery and management of acute severe ulcerative colitis.

Keywords: acute severe ulceration colitis; biologics; inflammatory bowel disease; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Drs. J.S, M.B., and E.T. have no conflicts of interest. A.C. is on the advisory board of and/or a consultant for and/or receives educational grants from Abbvie, Janssen, Pfizer, and Takeda.

Figures

Fig. 1
Fig. 1
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE)-II recommendations of therapeutic goals in ulcerative colitis. Adopted from Turner et al. Gastroenterology 2021;160:1570–1583. CRP, C-reactive protein; QOL, quality of life.
See this image and copyright information in PMC

References

    1. Shivashankar R, Tremaine W J, Harmsen W S, Loftus E V., Jr Incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010. Clin Gastroenterol Hepatol. 2017;15(06):857–863. - PMC - PubMed
    1. Swiss IBD Cohort Study Group . Safroneeva E, Vavricka S, Fournier N. Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients. Aliment Pharmacol Ther. 2015;42(05):540–548. - PubMed
    1. International Organization for the Study of IBD . Turner D, Ricciuto A, Lewis A. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(05):1570–1583. - PubMed
    1. VARSITY Study Group . Sands B E, Peyrin-Biroulet L, Loftus E V., Jr Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381(13):1215–1226. - PubMed
    1. Panes J, Jairath V, Levesque B G. Advances in use of endoscopy, radiology, and biomarkers to monitor inflammatory bowel diseases. Gastroenterology. 2017;152(02):362–373000. - PubMed